A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval

NCT02104648 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

203

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteer

Interventions

OTHER: Placebo RO4602522
DRUG: RO4602522
DRUG: RO4602522
DRUG: moxifloxacin
OTHER: moxifloxacin placebo

Sponsor

Hoffmann-La Roche